Stifel Reiterates Buy on Viking Therapeutics, Maintains $80 Price Target
Portfolio Pulse from Benzinga Newsdesk
Stifel analyst Annabel Samimy has reiterated a Buy rating on Viking Therapeutics (NASDAQ:VKTX) and maintained an $80 price target.
March 15, 2024 | 5:25 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Stifel analyst Annabel Samimy reiterates a Buy rating on Viking Therapeutics with an $80 price target.
Analyst ratings, especially from reputable firms like Stifel, can significantly influence investor sentiment and stock prices. A reiterated Buy rating and a high price target suggest strong confidence in the company's future performance, potentially leading to increased investor interest and a positive short-term price movement.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100